3M-backed CNS disorder therapy developer Impel priced its initial public offering in the middle of its range, giving it a $290m market cap.
US-based central nervous system (CNS) disorder-focused drug developer Impel NeuroPharma floated on Friday in an $80m initial public offering representing an exit for manufacturing group 3M.
The offering consisted of just over 5.3 million shares priced at $15.00 each, in the middle of the IPO’s $14 to $16 range, and they closed trading at the same price, giving the company a market capitalisation of about $290m.
Impel is working on therapeutics for diseases with high unmet medical needs and…
